Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus<i>nab</i>-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system

Ho, Rodrigo; Sebastião, Mariana Mioti; Carvalho, João Paulo Venezian de; Neves, Tomás; Nussbaum, M.

doi:10.1080/13696998.2020.1821039

Cited by 5 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Targeted therapeutics can lead to an improvement in the incremental cost‐effectiveness ratio per month of progression‐free survival 10,11 . In terms of cost effectiveness, treatment of advanced, PD‐L1–expressing TNBC with the combination of atezolizumab and nab‐paclitaxel resulted in an improvement in disease‐free survival and high quality‐adjusted life 12,13 .…”

Section: Introductionmentioning

confidence: 99%

Regulatory T cells: Their role in triple‐negative breast cancer progression and metastasis

Malla¹,

Padmaraju²,

Vempati³

et al. 2022

Cancer

View full text Add to dashboard Cite

Triple‐negative breast cancer (TNBC) is an aggressive and immunogenic subtype of breast cancer. This tumorigenicity is independent of hormonal or HER2 pathways because of a lack of respective receptor expression. TNBC is extremely prone to drug resistance and early recurrence because of T‐regulatory cell (Treg) infiltration into the tumor microenvironment (TME) in addition to other mechanisms like genomic instability. Tumor‐infiltrating Tregs interact with both tumor and stromal cells as well as extracellular matrix components in the TME and induce an immune‐suppressive phenotype. Hence, treatment of TNBC with conventional therapies remains challenging. Understanding the protective mechanism of Tregs in shielding TNBC from antitumor immune responses in the TME will pave the way for developing novel, immune‐based therapeutics. The current review focuses on the role of tumor‐infiltrating Tregs in tumor progression and metabolic reprogramming of the TME. The authors have extended their focus to oncotargeting Treg‐mediated immune suppression in breast cancer. Because of its potential role in the TME, modulating Treg activity may provide a novel strategic intervention to combat TNBC. Both under laboratory conditions and in clinical trials, currently available anticancer drugs and natural therapeutics as potential agents for targeting Tregs are explored.

show abstract

Section: Introductionmentioning

confidence: 99%

Regulatory T cells: Their role in triple‐negative breast cancer progression and metastasis

Malla¹,

Padmaraju²,

Vempati³

et al. 2022

Cancer

View full text Add to dashboard Cite

show abstract

“…Several harmonization studies for the diagnostic detection of PD-L1 expression were performed in different solid cancer entities with most studies focusing on non-small cell lung cancer (12,14,(26)(27)(28)(29)(30). The results of the study presented here are only partially mirrored by investigations in other tumor entities.…”

Section: Discussionmentioning

confidence: 81%

Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma

Ribbat‐Idel¹,

Dressler²,

Krupar³

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Background: The approval of immune checkpoint inhibitors in combination with specific diagnostic biomarkers presents new challenges to pathologists as tumor tissue needs to be tested for expression of programmed death-ligand 1 (PD-L1) for a variety of indications. As there is currently no requirement to use companion diagnostic assays for PD-L1 testing in Germany different clones are used in daily routine. While the correlation of staining results has been tested in various entities, there is no data for head and neck squamous cell carcinomas (HNSCC) so far.Methods: We tested five different PD-L1 clones (SP263, SP142, E1L3N, 22-8, 22C3) on primary HNSCC tumor tissue of 75 patients in the form of tissue microarrays. Stainings of both immune and tumor cells were then assessed and quantified by pathologists to simulate real-world routine diagnostics. The results were analyzed descriptively and the resulting staining pattern across patients was further investigated by principal component analysis and non-negative matrix factorization clustering.Results: Percentages of positive immune and tumor cells varied greatly. Both the resulting combined positive score as well as the eligibility for certain checkpoint inhibitor regimens was therefore strongly dependent on the choice of the antibody. No relevant co-clustering and low similarity of relative staining patterns across patients was found for the different antibodies.Conclusions: Performance of different diagnostic anti PD-L1 antibody clones in HNSCC is less robust and interchangeable compared to reported data from other tumor entities. Determination of PD-L1 expression is critical for therapeutic decision making and may be aided by back-to-back testing of different PD-L1 clones.

show abstract

Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plusnab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system

Cited by 5 publications

References 6 publications

Regulatory T cells: Their role in triple‐negative breast cancer progression and metastasis

Regulatory T cells: Their role in triple‐negative breast cancer progression and metastasis

Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma

Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review

Contact Info

Product

Resources

About